βeta blocker interruption after uncomplicated myocardial infarction: rationale and design of the randomized ABYSS trial - 14/03/23
, Guillaume Cayla, MD,PhD b, Emile Ferrari, MD,PhD c, Grégoire Range, MD d, Etienne Puymirat, MD,PhD e, f, Nicolas Delarche, MD g, Jean-Philippe Collet, MD,PhD a, Raphaelle Dumaine, MD h, Michel Slama, MD i, Laurent Payot, MD j, Mohamad E. Kasty, MD k, Karim Aacha, MD a, Eric Vicaut, MD,PhD l, Gilles Montalescot, MD,PhD aon behalf of the
ABYSS investigators of the ACTION Study Group,
Résumé |
Background |
The long-term use of β-blocker after myocardial infarction (MI) when global left ventricular ejection fraction (LVEF) is preserved has not been studied in the era of modern myocardial reperfusion and secondary prevention therapies. It is unknown whether β-blockers are useful in stable post-MI patients without reduced LVEF and without heart failure.
Methods |
The Assessment of β-blocker interruption 1 Year after an uncomplicated myocardial infarction on Safety and Symptomatic cardiac events requiring hospitalization (ABYSS) Trial enrolled in 49 centers in France, 3,700 patients with a prior (>6 months) history of MI and a LVEF >40%, chronically treated with a β-blocker and without any major cardiovascular event (MACE) in the past 6 months. These patients were randomized to interruption or continuation of their β-blocker therapy. The primary objective is to demonstrate the noninferiority of interruption vs continuation of the β-blocker therapy on the primary composite endpoint of all-cause death, stroke, MI, hospitalization for any cardiovascular reason at the end of follow-up (accrual follow-up) with a one-year minimum follow-up for the last randomized patient. Secondary objectives will focus on patient reported outcomes with the evaluation of the quality of life before and after randomization with the EQ5D-5L questionnaire. Enrolment has been completed.
Conclusion |
The ABYSS trial evaluates the cardiovascular safety of β-blocker interruption in stabilized post-MI patients without heart failure nor reduced LVEF. ABYSS trial is a reappraisal of β-blockers life-long therapy in stable post-MI patients without reduced LVEF.
Clinical trial registration |
NCT03498066 (clinicaltrials.gov)
Le texte complet de cet article est disponible en PDF.List of abbreviations : ABYSS, ACS, APHP, βB, CEC, DSMB, ECG, ITT, MI, LVEF, MACE, MRI, NSTEMI, PP, PROBE, STEMI
Plan
| ABYSS: The Assessment of β-blocker interruption one Year after an uncomplicated myocardial infarction on Safety and Symptomatic cardiac events requiring hospitalization NCT03498066 |
Vol 258
P. 168-176 - avril 2023 Retour au numéro
Article précédent
- Prehospital treatment with zalunfiban (RUC-4) in patients with ST‐ elevation myocardial infarction undergoing primary percutaneous coronary intervention: Rationale and design of the CELEBRATE trial
- Sem A.O.F. Rikken, Abi Selvarajah, Renicus S. Hermanides, Barry S. Coller, C. Michael Gibson, Christopher B. Granger, Frédéric Lapostolle, Sonja Postma, Henri van de Wetering, Risco C.W. van Vliet, Gilles Montalescot, Jurriën M. ten Berg, Arnoud W.J. van ’t Hof, CELEBRATE investigators
- Imaging in atrial fibrillation: A way to assess atrial fibrosis and remodeling to assist decision-making
- Raquel López-Galvez, José Miguel Rivera-Caravaca, Vanessa Roldán, Esteban Orenes-Piñero, María Asunción Esteve-Pastor, Cecilia López-García, Daniel Saura, Josefa González, Gregory Y.H. Lip, Francisco Marín
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?